Boston scientific receives fda approval for the polarx™ cryoablation system

First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems marlborough, mass. , aug. 8, 2023 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced it has received u.s. food and drug administration (fda) approval for the polarx™ cryoablation system.
BSX Ratings Summary
BSX Quant Ranking